Based on NCCN guidelines for Spindle Cell Sarcoma, what tests or steps might I be missing

Analysis of Marlo's Testing Against NCCN Sarcoma Guidelines

Based on the NCCN Guidelines for Soft Tissue Sarcoma and your comprehensive [ID removed] here's what you're doing well and what gaps might exist:

✅ WHAT YOU'RE DOING WELL

Your team has already implemented several key NCCN-recommended approaches:

Pathologic Assessment (Gold Standard)

• Multiple expert pathology reviews (CHLA, Mayo Clinic, pending St. Jude's)
• Immunohistochemistry (IHC) profiling to characterize the tumor
• Detailed histomorphologic examination

Molecular Characterization

• OncoKids testing (pediatric-focused molecular panel)
• RNA-Seq gene fusion analysis
• Chromosomal microarray (CMA)
• Exome sequencing (germline trio analysis)
• Whole genome sequencing (WGS) planned via CD Genomics

Ancillary Techniques

• IHC for smooth muscle markers and other proteins
• Multiple molecular testing modalities (addressing NCCN's recommendation that "each type of molecular testing is associated with test limitations")

---

⚠️ POTENTIAL GAPS BASED ON NCCN GUIDELINES

According to NCCN Soft Tissue Sarcoma Guidelines, pathologists should evaluate these specific features in the pathology report. Review your reports to confirm all are documented:

1. CRITICAL HISTOLOGIC GRADING PARAMETERS

The NCCN emphasizes these must be in the pathology report:

• Mitotic rate per 10 high-power fields (HPFs) - Is this explicitly stated in your pathology reports?
• Presence or absence of vascular invasion - Documented?
• Character of tumor margin (well-circumscribed vs. infiltrative) - Specified?
• Necrosis (presence/absence and extent) - Noted?
• Tumor grade (low-grade vs. high-grade) - Clearly assigned?

ACTION QUESTION FOR YOUR TEAM: Ask your pathologists: "Can you provide explicit documentation of mitotic rate, vascular invasion status, margin character, and necrosis extent? These are critical for NCCN staging and prognosis."

---

2. TUMOR, NODE, METASTASIS (TNM) STAGING

The NCCN Guidelines reference TNM staging (see ST-[address removed]-8 in their guidelines).

QUESTION TO ASK: "Has Marlo's tumor been formally staged using the current TNM system? What is the TNM stage, and how does it influence treatment recommendations?"

---

3. INFLAMMATORY INFILTRATE CHARACTERIZATION

NCCN notes: "For some tumors, characterization of the inflammatory infiltrate by immunohistochemical or other ancillary studies may be helpful (type and extent)."

Your BostonGene testing will address this through tumor microenvironment analysis, which is excellent. But confirm your pathology report documents:

• Type of inflammatory cells present
• Extent/density of infiltration
• Whether this has been characterized by IHC

---

4. EXPERT PATHOLOGY REVIEW COMPLETION

NCCN emphasizes: "Pathologists with expertise in STS should review the pathologic assessment."

STATUS CHECK:

• ✅ Mayo Clinic (Dr. [removed]) - completed
• ✅ CHLA - completed
• ⏳ St. Jude's - pending
• CONSIDER: Cleveland Clinic sarcoma pathology (noted in your treatment strategy document) - is this being pursued?

---

5. MOLECULAR TESTING STRATEGY - NCCN FRAMEWORK

NCCN recommends considering Next-Generation Sequencing (NGS) for:

• Determining patient eligibility for clinical trials
• Identifying actionable mutations not previously targeted
• Selecting patients for immunotherapy
• Cases with disease refractory to standard therapy

YOUR PLAN ADDRESSES THIS:

• WGS via CD Genomics ✅
• WES via BostonGene ✅
• RNA-seq via BostonGene ✅
• Archer Sequencing for fusion detection ✅

NCCN CAUTION: "NGS should not replace expert pathology review, as NGS only rarely results in a diagnosis change following expert review."

ACTION: Ensure all NGS results are reviewed by expert sarcoma pathologists (Mayo, CHLA, St. Jude's, Cleveland Clinic).

---

6. TISSUE QUALITY & DECALCIFICATION

NCCN notes: "Technically successful NGS on bone biopsies requires use of decalcification agents, such as ethylenediaminetetraacetic acid (EDTA), that do not interfere with genomic testing."

QUESTION FOR YOUR TEAM: Since Marlo's tumor is associated with cervical ribs (bone), confirm: "Was EDTA-based decalcification used if bone was included in the biopsy? This is critical for NGS accuracy."

---

7. TESTING COORDINATION & TIMING

Your "Optimal Tissue Testing Plan" document shows excellent coordination, but NCCN emphasizes:

• Avoid false-negative results by using complementary testing methods
• If one molecular test is negative when a mutation was clinically expected, discuss with the lab about alternative techniques

QUESTION TO ASK: "If any of our molecular tests come back negative but we clinically suspect a specific mutation, what's the plan to confirm with alternative testing methods?"

---

📋 SPECIFIC RECOMMENDATIONS FOR MARLO'S CASE

Before Next Biopsy/Tissue Submission:

1. Request comprehensive pathology report addendum that explicitly documents:

   • Mitotic rate (per 10 HPFs)
   • Vascular invasion (yes/no)
   • Margin character (circumscribed vs. infiltrative)
   • Necrosis (present/absent, extent)
   • Inflammatory infiltrate (type and extent)
   • TNM stage

2. Confirm tissue handling for NGS:

   • If bone included: EDTA decalcification used?
   • Tissue quality adequate for WGS/WES?
   • Fresh vs. frozen tissue specifications for each vendor?

3. Establish molecular testing hierarchy:

   • Which tests are primary vs. confirmatory?
   • What's the plan if results are discordant between platforms?

4. Document clinical context for NGS:

   • NCCN recommends NGS when: (a) clinical trial eligibility needed, (b) actionable mutations sought, (c) immunotherapy candidates, (d) refractory disease
   • Marlo fits multiple criteria—ensure this is documented for insurance/access purposes

---

🔬 ADVANCED CONSIDERATIONS (Beyond Standard NCCN)

Your team is already exploring these, which is excellent:

• Organoid & PDX development (TRACER, Certis) - enables functional testing
• Immunopeptidomics (neoantigen vaccine) - personalized immunotherapy
• FAP-targeted radioligand therapy - emerging approach for sarcomas
• CAR-T evaluation (St. Jude) - immunotherapy option

These go beyond standard NCCN recommendations but are appropriate for complex, treatment-resistant cases.

---

📌 SUMMARY: KEY QUESTIONS FOR YOUR ONCOLOGY TEAM

1. "Can we get a comprehensive pathology addendum documenting mitotic rate, vascular invasion, margin character, necrosis, and TNM stage?"

2. "What is Marlo's formal TNM stage, and how does this guide treatment sequencing?"

3. "For the upcoming biopsy, which tissue sites will give us the best tumor representation for all our planned testing?"

4. "If any molecular test comes back negative but we clinically suspect a specific mutation, what's our backup testing plan?"

5. "How will results from different molecular platforms (BostonGene, CD Genomics, Archer, etc.) be integrated and reviewed by expert pathologists?"

6. "Are there any NCCN-recommended tests we haven't yet performed that might be relevant to Marlo's specific diagnosis?"

---

📚 SOURCES

According to **NCCN Guidelines for Soft Tissue Sarcoma (Version 1.2025)